Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8454)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 10, 2017 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Tibaldi C, Lunghi A, Baldini E. Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. World J Clin Oncol 2017; 8(4): 320-328 [PMID: 28848698 DOI: 10.5306/wjco.v8.i4.320] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v8/i4/320.htm |
| Number | Citing Articles |
| 1 |
Carol C. Cheung, Penny Barnes, Gilbert Bigras, Scott Boerner, Jagdish Butany, Fiorella Calabrese, Christian Couture, Jean Deschenes, Hala El-Zimaity, Gabor Fischer, Pierre O. Fiset, John Garratt, Laurette Geldenhuys, C. Blake Gilks, Marius Ilie, Diana Ionescu, Hyun J. Lim, Lisa Manning, Adnan Mansoor, Robert Riddell, Catherine Ross, Sinchita Roy-Chowdhuri, Alan Spatz, Paul E. Swanson, Victor A. Tron, Ming-Sound Tsao, Hangjun Wang, Zhaolin Xu, Emina E. Torlakovic. Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). Applied Immunohistochemistry & Molecular Morphology 2019; 27(10): 699 doi: 10.1097/PAI.0000000000000800
|
| 2 |
Wan-Ling Liu, Yong-Qu Zhang, Xiang-Jie Luo, Yuan-Yuan Zhu, Liang Song, Zi-He Ming, Li-Xin Zhang, Meng-Jun Li, Rui-Chan Lv, Guo-Jun Zhang, Min Chen. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer. International Journal of Nanomedicine 2023; : 5141 doi: 10.2147/IJN.S417944
|
| 3 |
Hannan Gao, Yue Wu, Jiyun Shi, Xin Zhang, Tianyu Liu, Biao Hu, Bing Jia, Yakun Wan, Zhaofei Liu, Fan Wang. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. Journal for ImmunoTherapy of Cancer 2020; 8(2): e001156 doi: 10.1136/jitc-2020-001156
|
| 4 |
Jason M. Redman, Ravi A. Madan. Spotlight on atezolizumab and its potential as an oncology agent. Expert Review of Anticancer Therapy 2018; 18(8): 719 doi: 10.1080/14737140.2018.1483241
|
| 5 |
Andrea Anichini, Elena Tassi, Giulia Grazia, Roberta Mortarini. The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. Cancer Immunology, Immunotherapy 2018; 67(6): 1011 doi: 10.1007/s00262-018-2147-7
|
| 6 |
Min Du, Yumeng Cai, Yanrui Pang, Yuan Ji. A retrospective study of PD-L1 immunohistochemistry for hepatocellular carcinoma. iLIVER 2022; 1(3): 187 doi: 10.1016/j.iliver.2022.08.005
|
| 7 |
Yinfei Chen, Shiyu Zhu, Jiayu Fu, Jianguo Lin, Yan Sun, Gaochao Lv, Minhao Xie, Tao Xu, Ling Qiu. Development of a radiolabeled site-specific single-domain antibody positron emission tomography probe for monitoring PD-L1 expression in cancer. Journal of Pharmaceutical Analysis 2022; 12(6): 869 doi: 10.1016/j.jpha.2022.09.001
|